China’s top securities regulator has signaled restarting a regulatory pathway to allow for unprofitable biotechnology and medical technology start-ups to go public on the Shanghai Stock Exchange (SSE).
The restoration of the special initial public offering (IPO) process, which was first introduced along with the launch of the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?